Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 33

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 33
---
 conversion price as low as the Floor Price. If all of the 9,750 shares of Series E Preferred Stock, including the 3,816 shares of Series E Preferred Stock and the 5,934 shares of Series E Preferred Stock that may be issued in additional closings, were converted at the Floor Price following an Alternate Conversion resulting in the reset of the conversion price to the Floor Price, the October 2025 Investors would own 9,750,000 shares of Common Stock, or approximately 31.9% of the outstanding shares of Common Stock. If such shares were converted at the Floor Price, with the application of the Required Premium, the October 2025 Investors would own 12,187,50 shares of Common Stock, or approximately 36.9% of the outstanding shares of Common Stock. Although the COD does not contain the adjustments to the Alternate Conversion procedures contained in the terms of the Company’s outstanding Series A Preferred Stock or Series C Preferred Stock applicable when the Alternate Conversion Price is less than the Floor Price, the Floor Price does not apply to adjustments in connection with the issuance of securities at prices below the then -currentconversion price. As a result, following such issuances, the conversion price may be adjusted to a price below the Floor Price, resulting in the issuance of more than 195million shares of Common Stock. In addition, under the terms of the Series E Preferred Stock, an October 2025 Investor may not convert the Series E Preferred Stock to the extent (but only to the extent) such October 2025 Investor or any of its affiliates would beneficially own a number of shares of Common Stock which would exceed 4.99%, or, at the election of the October 2025 Investor, a number of shares of Common Stock which would exceed 9.99%. October 2025 Private Placement In October 2025, the Company consummated the October 2025 Private Placement of 3,816 shares of Series E Preferred Stock pursuant to the October 2025 Securities Purchase Agreement, dated October 14, 2025, as amended pursuant to the Amendment No. 1 to the Securities Purchase Agreement, dated October 15, 2025 (collectively, the “October 2025 Securities Purchase Agreement”), for aggregate proceeds of approximately $2.25 million, and agreed to issue up to 5,934 additional shares of Series E Preferred Stock for proceeds of up to $4.75 million at one or more additional closings. Each additional closing under the